|
1
|
Jamison DT, Summers LH, Alleyne G, Arrow
KJ, Berkley S, Binagwaho A, Bustreo B, Evans D, Feachem RGA, Frenk
J, et al: Global health 2035: A world converging within a
generation. Lancet. 382:1898–1955. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Raftery AE, Li N, Ševčíková H, Gerland P
and Heilig GK: Bayesian probabilistic population projections for
all countries. Proc Natl Acad Sci USA. 109:13915–13921.
2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Saeedi P, Petersohn I, Salpea P, Malanda
B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA,
Ogurtsova K, et al: Global and regional diabetes prevalence
estimates for 2019 and projections for 2030 and 2045: Results from
the International Diabetes Federation Diabetes Atlas, 9(th)
edition. Diabetes Res Clin Pract. 157(107843)2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dickler MN, Tolaney SM, Rugo HS, Cortés J,
Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E,
et al: MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6
inhibitor, as a single agent, in patients with refractory
HR+/HER2- metastatic breast cancer. Clin
Cancer Res. 23:5218–5224. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
MONARCH 2: Abemaciclib, in combination with Fulvestrant in women
with HR+/HER2- advanced breast cancer who had
progressed while receiving endocrine therapy. J Clin Oncol.
35:2875–2884. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Goetz MP, Toi M, Campone M, Sohn J,
Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, et
al: MONARCH 3: Abemaciclib, as initial therapy for advanced breast
cancer. J Clin Oncol. 35:3638–3646. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Draeger E: Clinical profile of
glimepiride. Diabetes Res Clin Pract. 28:139–146. 1995.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Draeger KE, Wernicke-Panten K, Lomp HJ,
Schüler E and Rosskamp R: Long-term treatment of type 2 diabetic
patients with the new oral antidiabetic agent glimepiride (Amaryl):
A double-blind comparison with glibenclamide. Horm Metab Res.
28:419–425. 1996.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Badian M, Korn A, Lehr KH, Malerczyk V and
Waldhäusl W: Absolute bioavailability of Glimepiride (Amaryl) after
oral administration. Drug Metabol Drug Interact. 11:331–339.
1994.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Niemi M, Cascorbi I, Timm R, Kroemer HK,
Neuvonen PJ and Kivistö KT: Glyburide and glimepiride
pharmacokinetics in subjects with different CYP2C9 genotypes. Clin
Pharmacol Ther. 72:326–332. 2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Otagiri M: Study on binding of drug to
serum protein. Yakugaku Zasshi. 129:413–425. 2009.PubMed/NCBI View Article : Google Scholar : (In Japanese).
|
|
13
|
Meyer MC and Guttman DE: The binding of
drugs by plasma proteins. J Pharm Sci. 57:895–918. 1968.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jusko WJ and Gretch M: Plasma and tissue
protein binding of drugs in pharmacokinetics. Drug Metab Rev.
5:43–140. 1976.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Vallner JJ: Binding of drugs by albumin
and plasma protein. J Pharm Sci. 66:447–465. 1977.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Langtry HD and Balfour JA: Glimepiride. A
review of its use in the management of type 2 diabetes mellitus.
Drugs. 55:563–584. 1998.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang D, Sun Y, Li W, Ye F, Zhang Y, Guo Y,
Zhang DY and Suo J: Antiproliferative effects of the CDK6 inhibitor
PD0332991 and its effect on signaling networks in gastric cancer
cells. Int J Mol Med. 41:2473–2484. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Toogood PL, Harvey PJ, Repine JT, Sheehan
DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T,
et al: Discovery of a potent and selective inhibitor of
cyclin-dependent kinase 4/6. J Med Chem. 48:2388–2406.
2005.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell
RG and Wu K: Recent advances of highly selective CDK4/6 inhibitors
in breast cancer. J Hematol Oncol. 10(97)2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Li B, He H, Tao BB, Zhao ZY, Hu GH, Luo C,
Chen JX, Ding XH, Sheng P, Dong Y, et al: Knockdown of CDK6
enhances glioma sensitivity to chemotherapy. Oncol Rep. 28:909–914.
2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Fujiwara Y, Tamura K, Kondo S, Tanabe Y,
Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, et
al: Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a
single agent for Japanese patients with advanced cancer. Cancer
Chemother Pharmacol. 78:281–288. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Patnaik A, Rosen LS, Tolaney SM, Tolcher
AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW,
Hilton JF, et al: Efficacy and safety of abemaciclib, an inhibitor
of CDK4 and CDK6, for patients with breast cancer, non-small cell
lung cancer, and other solid tumors. Cancer Discov. 6:740–753.
2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tate SC, Sykes AK, Kulanthaivel P, Chan
EM, Turner PK and Cronier DM: A population pharmacokinetic and
pharmacodynamic analysis of abemaciclib, in a phase I clinical
trial in cancer patients. Clin Pharmacokinet. 57:335–344.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Rosenkranz B: Pharmacokinetic basis for
the safety of glimepiride in risk groups of NIDDM patients. Horm
Metab Res. 28:434–439. 1996.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kacevska M, Robertson GR, Clarke SJ and
Liddle C: Inflammation and CYP3A4-mediated drug metabolism in
advanced cancer: Impact and implications for chemotherapeutic drug
dosing. Expert Opin Drug Metab Toxicol. 4:137–149. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fahy BN, Guo T and Ghose R: Impact of
hepatic malignancy on CYP3A4 gene expression. J Surg Res.
178:768–772. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Rosenkranz B, Profozic V, Metelko Z,
Mrzljak V, Lange C and Malerczyk V: Pharmacokinetics and safety of
glimepiride at clinically effective doses in diabetic patients with
renal impairment. Diabetologia. 39:1617–1624. 1996.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hou L, Zhao T, Liu Y and Zhang Y: Efficacy
and safety of sitagliptin compared with sulfonylurea therapy in
patients with type 2 diabetes showing inadequately controlled
glycosylated hemoglobin with metformin monotherapy: A
meta-analysis. Exp Ther Med. 9:1528–1536. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
DeFronzo RA: Pharmacologic therapy for
type 2 diabetes mellitus. Ann Intern Med. 131:281–303.
1999.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Inzucchi SE: Oral antihyperglycemic
therapy for type 2 diabetes: Scientific review. JAMA. 287:360–372.
2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Levey AS, Perrone RD and Madias NE: Serum
creatinine and renal function. Annu Rev Med. 39:465–490.
1988.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pun KK, Young RTT, Wang C, Tam CF and Ho
PWM: The use of glucagon challenge tests in the diagnostic
evaluation of hypoglycemia due to hepatoma and insulinoma. J Clin
Endocrinol Metab. 67:546–550. 1988.PubMed/NCBI View Article : Google Scholar
|
